Time to Reconsider CYTODYN INC (OTCMKTS:CYDY) After Less Short Sellers?

CytoDyn Inc. (OTCMKTS:CYDY) Logo

The stock of CYTODYN INC (OTCMKTS:CYDY) registered a decrease of 10.2% in short interest. CYDY’s total short interest was 344,300 shares in December as published by FINRA. Its down 10.2% from 383,400 shares, reported previously. With 736,400 shares average volume, it will take short sellers 1 days to cover their CYDY’s short positions.

The stock decreased 1.34% or $0.008 during the last trading session, reaching $0.591. About 36,238 shares traded. CytoDyn Inc. (OTCMKTS:CYDY) has 0.00% since December 7, 2017 and is . It has underperformed by 15.62% the S&P500.

CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection. The company has market cap of $170.34 million. The Company’s lead product under development for HIV infection include PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. It currently has negative earnings.

More notable recent CytoDyn Inc. (OTCMKTS:CYDY) news were published by: Seekingalpha.com which released: “CytoDyn’s PRO 140: Setting The Record Straight – Seeking Alpha” on September 17, 2018, also Seekingalpha.com with their article: “CytoDyn to hold investment community conference call on September 13 – Seeking Alpha” published on September 11, 2018, Seekingalpha.com published: “Biotech Analysis Central Pharma News: Cytodyn’s Acquisition, Novartis Exits Antibotic Research, Advaxis’ FDA Hold Removed – Seeking Alpha” on July 15, 2018. More interesting news about CytoDyn Inc. (OTCMKTS:CYDY) were released by: Seekingalpha.com and their article: “CytoDyn’s PRO 140: A Potential Victim Of Poor Clinical Development – Seeking Alpha” published on September 13, 2018 as well as Seekingalpha.com‘s news article titled: “CytoDyn Merger Does More Than Expand Into Metastatic Cancer – Seeking Alpha” with publication date: October 01, 2018.

CytoDyn Inc. (OTCMKTS:CYDY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.